Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: An increased risk of angioedema

Hypertension

Volumn 54, Issue 3, 2009, Pages 468-470

  Grouzmann, Eric ^a   Livio, Françoise ^a   Buclin, Thierry ^a  

^a University of Lausanne Medical Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; OMAPATRILAT; SITAGLIPTIN; SUBSTANCE P; VILDAGLIPTIN; ADAMANTANE; DRUG DERIVATIVE; NITRILE; PYRROLIDINE DERIVATIVE;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; CYSTITIS; DIABETES CONTROL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE TOLERANCE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; POLYPHARMACY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHINOPHARYNGITIS; RISK ASSESSMENT; UNITED STATES; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; RISK FACTOR;

ADAMANTANE; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, CD26; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SYNERGISM; HUMANS; MODELS, BIOLOGICAL; NITRILES; PYRROLIDINES; RISK FACTORS;

EID: 70349237185     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135244     Document Type: Note

References (18)

1. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/ dm/pubs/statistics/. Accessed May 21, 2009.
2. The State of Healthcare Quality, Annual Report. Available at: http://www. ncqa.org/tabid/543/Default.aspx. Accessed January 9, 2008.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
4. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298: 194-206. (Pubitemid 47057766)
5. European Medicines Agency. EPARS for authorised medicinal products for human use. Available at: http://www.emea.europa.eu/humandocs/ Humans/EPAR/januvia/januvia.htm. Accessed May 21, 2009.
6. European Medicines Agency. EPARS for authorised medicinal products for human use. Available at: http://www.emea.europa.eu/humandocs/ Humans/EPAR/galvus/galvus.htm. Accessed May 21, 2009.
7. De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today. 1999;20:367-375.
8. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51:141-147.
9. Grouzmann E, Monod M, Landis B, Wilk S, Brakch N, Nicoucar K, Giger R, Malis D, Szalay-Quinodoz I, Cavadas C, Morel DR, Lacroix JS. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. 2002;16:1132-1134.
10. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA dipeptidyl peptidase-iv inhibitor use associated with increased risk of ace inhibitorassociated angioedema. Hypertension. 2009;54:516-523.
11. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
12. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensinconverting enzyme inhibitors. Hypertension. 2008;51:1624-1630.
13. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
14. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, Levy E. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642.
15. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella CM. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168-1172.
16. IMSNationalPrescriptionAuditPLUS.Availableat:http://www.imshealth. com/portal/site/imshealth. Accessed May 21, 2009.
17. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30:487-496.
18. Guidance for Industry- Diabetes Mellitus- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available at: http:// www.fda.gov/cder/guidance/8576fnl.pdf. Accessed May 21, 2009.